---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-098421"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:58:54.843030+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics raises up to $7M via Series E convertible preferred private placement

## Summary
- Initial closing of ~$1.8M; Series E convertible at $1,000 stated value, conversion price $4.1625 per share.
- Series C and D conversion price reduced to $1.76 as consent for pari passu treatment with Series E.
- Company to seek stockholder approval by Oct 31, 2025 for lower conversion; meeting target Dec 31, 2025.
- Bankruptcy trigger and company optional redemption each at 25% premium.
- Registration rights agreement filed to register resale of conversion shares.

## SEC filing metadata
- accession: 0001213900-25-098421
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/0001213900-25-098421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/ea0260318-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-098421
- JSON: https://secwatch.observer/filing/0001213900-25-098421.json
- Plain text: https://secwatch.observer/filing/0001213900-25-098421.txt

## Key facts
- Equity Issuances
  CERO THERAPEUTICS HOLDINGS, INC. issued up to 9,750 shares of the Company's Series E convertible preferred stock of preferred stock to certain accredited investors named therein (the "PIPE Investors") for aggregate purchase price of up to $7 million.
  - Security: preferred stock
  - Shares: up to 9,750 shares of the Company's Series E convertible preferred stock
  - Purchaser: certain accredited investors named therein (the "PIPE Investors")
  - Consideration: aggregate purchase price of up to $7 million
  source text: Pursuant to the Securities Purchase Agreement, up to 9,750 shares of the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “ Series E Preferred Stock ”) shall be purchased for an aggregate purchase price of up to $7 million in one or more closings
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/0001213900-25-098421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.